Antibiotic Therapy of Plague: A Review - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Biomolecules Année : 2021

Antibiotic Therapy of Plague: A Review


Plague-a deadly disease caused by the bacterium Yersinia pestis-is still an international public health concern. There are three main clinical forms: bubonic plague, septicemic plague, and pulmonary plague. In all three forms, the symptoms appear suddenly and progress very rapidly. Early antibiotic therapy is essential for countering the disease. Several classes of antibiotics (e.g., tetracyclines, fluoroquinolones, aminoglycosides, sulfonamides, chloramphenicol, rifamycin, and beta-lactams) are active in vitro against the majority of Y. pestis strains and have demonstrated efficacy in various animal models. However, some discrepancies have been reported. Hence, health authorities have approved and recommended several drugs for prophylactic or curative use. Only monotherapy is currently recommended; combination therapy has not shown any benefits in preclinical studies or case reports. Concerns about the emergence of multidrug-resistant strains of Y. pestis have led to the development of new classes of antibiotics and other therapeutics (e.g., LpxC inhibitors, cationic peptides, antivirulence drugs, predatory bacteria, phages, immunotherapy, host-directed therapy, and nutritional immunity). It is difficult to know which of the currently available treatments or therapeutics in development will be most effective for a given form of plague. This is due to the lack of standardization in preclinical studies, conflicting data from case reports, and the small number of clinical trials performed to date.

Dates et versions

hal-03592958 , version 1 (01-03-2022)



Florent Sebbane, Nadine Lemaître. Antibiotic Therapy of Plague: A Review. Biomolecules, 2021, 11 (5), ⟨10.3390/biom11050724⟩. ⟨hal-03592958⟩
29 Consultations
0 Téléchargements



Gmail Mastodon Facebook X LinkedIn More